Palanas, Jane D.
HRN: 23-90-85 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/21/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/21/2023
10/27/2023
IV
230mg
Q8
Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Unspecified Sepsis Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes